5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Cerebrovascular O
Adverse O
Reactions O
: O
Increased O
incidence O
of O
cerebrovascular O
adverse O
events O
( O
e.g. O
, O
stroke O
, O
transient O
ischemic O
attack O
) O
has O
been O
seen O
in O
elderly O
patients O
with O
dementia-related O
psychoses O
treated O
with O
atypical O
antipsychotic O
drugs O
( O
5.3 O
) O
* O
Neuroleptic O
Malignant O
Syndrome O
( O
NMS O
) O
: O
Manage O
with O
immediate O
discontinuation O
and O
close O
monitoring O
( O
5.4 O
) O
* O
* O
∘ O
Hyperglycemia O
and O
Diabetes O
Mellitus O
: O
Monitor O
patients O
for O
symptoms O
of O
hyperglycemia O
including O
polydipsia O
, O
polyuria O
, O
polyphagia O
, O
and O
weakness O
. O

Monitor O
glucose O
regularly O
in O
patients O
with O
diabetes O
or O
at O
risk O
for O
diabetes O
* O
∘ O
Dyslipidemia O
: O
Undesirable O
alterations O
have O
been O
observed O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

Appropriate O
clinical O
monitoring O
is O
recommended O
, O
including O
fasting O
blood O
lipid O
testing O
at O
the O
beginning O
of O
, O
and O
periodically O
, O
during O
treatment O
* O
∘ O
Weight O
Gain O
: O
Gain O
in O
body O
weight O
has O
been O
observed O
; O
clinical O
monitoring O
of O
weight O
is O
recommended O
Metabolic O
Changes O
: O
Atypical O
antipsychotics O
have O
been O
associated O
with O
metabolic O
changes O
. O

These O
metabolic O
changes O
include O
hyperglycemia O
, O
dyslipidemia O
, O
and O
weight O
gain O
( O
5.5 O
) O
* O
Tardive O
Dyskinesia O
: O
Discontinue O
if O
clinically O
appropriate O
( O
5.6 O
) O
* O
Hypotension O
: O
Use O
with O
caution O
in O
patients O
with O
known O
cardiovascular O
or O
cerebrovascular O
disease O
( O
5.7 O
) O
* O
Increased O
Blood O
Pressure O
in O
Children O
and O
Adolescents O
: O
Monitor O
blood O
pressure O
at O
the O
beginning O
of O
, O
and O
periodically O
during O
treatment O
in O
children O
and O
adolescents O
( O
5.9 O
) O
* O
Leukopenia O
, O
Neutropenia O
and O
Agranulocytosis O
: O
Monitor O
complete O
blood O
count O
frequently O
during O
the O
first O
few O
months O
of O
treatment O
in O
patients O
with O
a O
pre-existing O
low O
white O
cell O
count O
or O
a O
history O
of O
leukopenia/neutropenia O
and O
discontinue O
SEROQUEL O
at O
the O
first O
sign O
of O
a O
decline O
in O
WBC O
in O
absence O
of O
other O
causative O
factors O
( O
5.10 O
) O
* O
Cataracts O
: O
Lens O
changes O
have O
been O
observed O
in O
patients O
during O
long-term O
quetiapine O
treatment O
. O

Lens O
examination O
is O
recommended O
when O
starting O
treatment O
and O
at O
6-month O
intervals O
during O
chronic O
treatment O
( O
5.11 O
) O
5.1 O
Increased O
Mortality O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
Elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death B-NonOSE_AE
. O

Analysis O
of O
17 O
placebo-controlled O
trials O
( O
modal O
duration O
of O
10 O
weeks O
) O
, O
largely O
in O
patients O
taking O
atypical O
antipsychotic O
drugs O
, O
revealed O
a O
risk O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
of O
between O
1.6 O
to O
1.7 O
times O
the O
risk O
of O
death B-NonOSE_AE
in O
placebo-treated O
patients O
. O

Over O
the O
course O
of O
a O
typical O
10-week O
controlled O
trial O
, O
the O
rate O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
was O
about O
4.5 O
% O
, O
compared O
to O
a O
rate O
of O
about O
2.6 O
% O
in O
the O
placebo O
group O
. O

Although O
the O
causes O
of O
death B-NonOSE_AE
were O
varied O
, O
most O
of O
the O
deaths B-NonOSE_AE
appeared O
to O
be O
either O
cardiovascular I-NonOSE_AE
( O
e.g. O
, O
heart B-NonOSE_AE
failure I-NonOSE_AE
, O
sudden B-NonOSE_AE
death I-NonOSE_AE
) O
or O
infectious B-NonOSE_AE
( O
e.g. O
, O
pneumonia B-NonOSE_AE
) O
in O
nature O
. O

Observational O
studies O
suggest O
that O
, O
similar O
to O
atypical O
antipsychotic O
drugs O
, O
treatment O
with O
conventional O
antipsychotic O
drugs O
may O
increase O
mortality B-NonOSE_AE
. O

The O
extent O
to O
which O
the O
findings O
of O
increased O
mortality B-NonOSE_AE
in O
observational O
studies O
may O
be O
attributed O
to O
the O
antipsychotic O
drug O
as O
opposed O
to O
some O
characteristic O
( O
s O
) O
of O
the O
patients O
is O
not O
clear O
. O

SEROQUEL O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
] O
. O

5.2 O
Suicidal O
Thoughts O
and O
Behaviors O
in O
Adolescents O
and O
Young O
Adults O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-NonOSE_AE
and O
certain O
other O
psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and O
the O
emergence O
of O
suicidality B-NonOSE_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
- I-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
antidepressant O
drugs O
in O
over O
4400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-NonOSE_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
differences O
( O
drug O
vs O
. O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1000 O
patients O
treated O
) O
are O
provided O
in O
Table O
2 O
. O

Table O
2 O
: O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality O
per O
1000 O
Patients O
Treated O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1000 O
Patients O
Treated O
Increases I-OSE_Labeled_AE
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
=65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-NonOSE_AE
is I-NonOSE_AE
persistently I-NonOSE_AE
worse I-NonOSE_AE
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening B-NonOSE_AE
depression I-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
healthcare O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
SEROQUEL O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Screening O
Patients O
for O
Bipolar B-NonOSE_AE
Disorder I-NonOSE_AE
: O
A O
major B-NonOSE_AE
depressive I-NonOSE_AE
episode I-NonOSE_AE
may O
be O
the O
initial O
presentation O
of O
bipolar B-NonOSE_AE
disorder I-NonOSE_AE
. O

It O
is O
generally O
believed O
( O
though O
not O
established O
in O
controlled O
trials O
) O
that O
treating O
such O
an O
episode O
with O
an O
antidepressant O
alone O
may O
increase O
the O
likelihood O
of O
precipitation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
mixed I-NonOSE_AE
/ I-NonOSE_AE
manic I-NonOSE_AE
episode I-NonOSE_AE
in I-NonOSE_AE
patients I-NonOSE_AE
at I-NonOSE_AE
risk I-NonOSE_AE
for I-NonOSE_AE
bipolar I-NonOSE_AE
disorder I-NonOSE_AE
. O

Whether O
any O
of O
the O
symptoms O
described O
above O
represent O
such O
a O
conversion O
is O
unknown O
. O

However O
, O
prior O
to O
initiating O
treatment O
with O
an O
antidepressant O
, O
including O
SEROQUEL O
, O
patients O
with O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-NonOSE_AE
disorder I-NonOSE_AE
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric O
history O
, O
including O
a O
family O
history O
of O
suicide B-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

5.3 O
Cerebrovascular O
Adverse O
Reactions O
, O
Including O
Stroke O
, O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
In O
placebo-controlled O
trials O
with O
risperidone O
, O
aripiprazole O
, O
and O
olanzapine O
in O
elderly O
subjects O
with O
dementia B-Not_AE_Candidate
, O
there O
was O
a O
higher O
incidence O
of O
cerebrovascular B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
( O
cerebrovascular B-NonOSE_AE
accidents I-NonOSE_AE
and O
transient B-NonOSE_AE
ischemic I-NonOSE_AE
attacks I-NonOSE_AE
) O
including O
fatalities B-NonOSE_AE
compared O
to O
placebo-treated O
subjects O
. O

SEROQUEL O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
also O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

5.4 O
Neuroleptic O
Malignant O
Syndrome O
( O
NMS O
) O
A O
potentially O
fatal B-NonOSE_AE
symptom O
complex O
sometimes O
referred O
to O
as O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
has O
been O
reported O
in O
association O
with O
administration O
of O
antipsychotic O
drugs O
, O
including O
SEROQUEL O
. O

Rare O
cases O
of O
NMS B-OSE_Labeled_AE
have O
been O
reported O
with O
SEROQUEL O
. O

Clinical O
manifestations O
of O
NMS B-NonOSE_AE
are O
hyperpyrexia B-NonOSE_AE
, O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
, O
altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
, O
and O
evidence O
of O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
irregular B-NonOSE_AE
pulse O
or O
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
and O
cardiac B-NonOSE_AE
dysrhythmia I-NonOSE_AE
) O
. O

Additional O
signs O
may O
include O
elevated B-NonOSE_AE
creatinine I-NonOSE_AE
phosphokinase I-NonOSE_AE
, O
myoglobinuria B-NonOSE_AE
( O
rhabdomyolysis B-NonOSE_AE
) O
and O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
. O

The O
diagnostic O
evaluation O
of O
patients O
with O
this O
syndrome O
is O
complicated O
. O

In O
arriving O
at O
a O
diagnosis O
, O
it O
is O
important O
to O
exclude O
cases O
where O
the O
clinical O
presentation O
includes O
both O
serious O
medical O
illness O
( O
e.g. O
, O
pneumonia B-NonOSE_AE
, O
systemic B-NonOSE_AE
infection I-NonOSE_AE
, O
etc O
. O
) O

and O
untreated O
or O
inadequately O
treated O
extrapyramidal B-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
EPS I-NonOSE_AE
) O
. O

Other O
important O
considerations O
in O
the O
differential O
diagnosis O
include O
central B-NonOSE_AE
anticholinergic I-NonOSE_AE
toxicity I-NonOSE_AE
, O
heat B-NonOSE_AE
stroke I-NonOSE_AE
, O
drug B-NonOSE_AE
fever I-NonOSE_AE
and O
primary B-NonOSE_AE
central I-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
( I-NonOSE_AE
CNS I-NonOSE_AE
) I-NonOSE_AE
pathology I-NonOSE_AE
. O

The O
management O
of O
NMS B-NonOSE_AE
should O
include O
: O
1 O
) O
immediate O
discontinuation O
of O
antipsychotic O
drugs O
and O
other O
drugs O
not O
essential O
to O
concurrent O
therapy O
; O
2 O
) O
intensive O
symptomatic O
treatment O
and O
medical O
monitoring O
; O
and O
3 O
) O
treatment O
of O
any O
concomitant O
serious O
medical O
problems O
for O
which O
specific O
treatments O
are O
available O
. O

There O
is O
no O
general O
agreement O
about O
specific O
pharmacological O
treatment O
regimens O
for O
NMS B-NonOSE_AE
. O

If O
a O
patient O
requires O
antipsychotic O
drug O
treatment O
after O
recovery O
from O
NMS B-NonOSE_AE
, O
the O
potential O
reintroduction O
of O
drug O
therapy O
should O
be O
carefully O
considered O
. O

The O
patient O
should O
be O
carefully O
monitored O
since O
recurrences O
of O
NMS B-NonOSE_AE
have O
been O
reported O
. O

5.5 O
Metabolic O
Changes O
Atypical O
antipsychotic O
drugs O
have O
been O
associated O
with O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
that O
include O
hyperglycemia B-OSE_Labeled_AE
/ O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
dyslipidemia B-OSE_Labeled_AE
, O
and O
body B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

While O
all O
of O
the O
drugs O
in O
the O
class O
have O
been O
shown O
to O
produce O
some O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
each O
drug O
has O
its O
own O
specific O
risk O
profile O
. O

In O
some O
patients O
, O
a O
worsening B-NonOSE_AE
of I-NonOSE_AE
more O
than O
one O
of O
the O
metabolic O
parameters O
of O
weight I-NonOSE_AE
, O
blood O
glucose O
, O
and O
lipids O
was O
observed O
in O
clinical O
studies O
. O

Changes B-NonOSE_AE
in I-NonOSE_AE
these I-NonOSE_AE
metabolic I-NonOSE_AE
profiles O
should O
be O
managed O
as O
clinically O
appropriate O
. O

Hyperglycemia O
and O
Diabetes O
Mellitus O
Hyperglycemia B-OSE_Labeled_AE
, O
in O
some O
cases O
extreme O
and O
associated O
with O
ketoacidosis B-OSE_Labeled_AE
or O
hyperosmolar B-OSE_Labeled_AE
coma I-OSE_Labeled_AE
or O
death B-NonOSE_AE
, O
has O
been O
reported O
in O
patients O
treated O
with O
atypical O
antipsychotics O
, O
including O
quetiapine O
. O

Assessment O
of O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
glucose B-NonOSE_AE
abnormalities I-NonOSE_AE
is O
complicated O
by O
the O
possibility O
of O
an O
increased O
background O
risk O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
patients O
with O
schizophrenia B-Not_AE_Candidate
and O
the O
increasing O
incidence O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
the O
general O
population O
. O

Given O
these O
confounders O
, O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
hyperglycemia B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
is O
not O
completely O
understood O
. O

However O
, O
epidemiological O
studies O
suggest O
an O
increased O
risk O
of O
treatment-emergent O
hyperglycemia B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
treated O
with O
the O
atypical O
antipsychotics O
. O

Precise O
risk O
estimates O
for O
hyperglycemia B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
in O
patients O
treated O
with O
atypical O
antipsychotics O
are O
not O
available O
. O

Patients O
with O
an O
established O
diagnosis O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
who O
are O
started O
on O
atypical O
antipsychotics O
should O
be O
monitored O
regularly O
for O
worsening B-NonOSE_AE
of I-NonOSE_AE
glucose I-NonOSE_AE
control I-NonOSE_AE
. O

Patients O
with O
risk O
factors O
for O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
( O
e.g. O
, O
obesity B-Not_AE_Candidate
, O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
) O
who O
are O
starting O
treatment O
with O
atypical O
antipsychotics O
should O
undergo O
fasting O
blood O
glucose O
testing O
at O
the O
beginning O
of O
treatment O
and O
periodically O
during O
treatment O
. O

Any O
patient O
treated O
with O
atypical O
antipsychotics O
should O
be O
monitored O
for O
symptoms O
of O
hyperglycemia B-NonOSE_AE
including O
polydipsia B-NonOSE_AE
, O
polyuria B-NonOSE_AE
, O
polyphagia B-NonOSE_AE
, O
and O
weakness B-NonOSE_AE
. O

Patients O
who O
develop O
symptoms O
of O
hyperglycemia B-NonOSE_AE
during O
treatment O
with O
atypical O
antipsychotics O
should O
undergo O
fasting O
blood O
glucose O
testing O
. O

In O
some O
cases O
, O
hyperglycemia B-NonOSE_AE
has O
resolved O
when O
the O
atypical O
antipsychotic O
was O
discontinued O
; O
however O
, O
some O
patients O
required O
continuation O
of O
anti-diabetic O
treatment O
despite O
discontinuation O
of O
the O
suspect O
drug O
. O

Adults O
: O
Table O
3 O
: O
Fasting O
Glucose O
- O
Proportion O
of O
Patients O
Shifting O
to O
> O
=126 O
mg/dL O
in O
Short-Term O
( O
< O
=12 O
weeks O
) O
Placebo-Controlled O
StudiesIncludes O
SEROQUEL O
and O
SEROQUEL O
XR O
data O
. O

Laboratory O
Analyte O
Category O
Change O
( O
At O
Least O
Once O
) O
from O
Baseline O
Treatment O
Arm O
N O
Patients O
n O
( O
% O
) O
Fasting B-NonOSE_AE
Glucose I-NonOSE_AE
Normal O
to O
High O
( O
< O
100 O
mg/dL O
to O
> O
=126 O
mg/dL O
) O
Quetiapine O
2907 O
71 O
( O
2.4 O
% O
) O
Placebo O
1346 O
19 O
( O
1.4 O
% O
) O
Borderline I-NonOSE_AE
to I-NonOSE_AE
High I-NonOSE_AE
( O
> O
= O
100 O
mg/dL O
and O
< O
126 O
mg/dL O
to O
> O
=126 O
mg/dL O
) O
Quetiapine O
572 O
67 O
( O
11.7 O
% O
) O
Placebo O
279 O
33 O
( O
11.8 O
% O
) O
In O
a O
24-week O
trial O
( O
active-controlled O
, O
115 O
patients O
treated O
with O
SEROQUEL O
) O
designed O
to O
evaluate O
glycemic O
status O
with O
oral O
glucose O
tolerance O
testing O
of O
all O
patients O
, O
at O
week O
24 O
the O
incidence O
of O
a O
treatment-emergent O
post-glucose O
challenge O
glucose B-OSE_Labeled_AE
level I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
was O
1.7 O
% O
and O
the O
incidence O
of O
a O
fasting B-OSE_Labeled_AE
treatment-emergent O
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
level I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
was O
2.6 O
% O
. O

The O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
was O
3.2 O
mg/dL O
and O
mean O
change B-OSE_Labeled_AE
in I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
- I-OSE_Labeled_AE
hour I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
was O
-1.8 O
mg/dL O
for O
quetiapine O
. O

In O
2 O
long-term O
placebo-controlled O
randomized O
withdrawal O
clinical O
trials O
for O
bipolar B-Not_AE_Candidate
I I-Not_AE_Candidate
disorder I-Not_AE_Candidate
maintenance O
, O
mean O
exposure O
of O
213 O
days O
for O
SEROQUEL O
( O
646 O
patients O
) O
and O
152 O
days O
for O
placebo O
( O
680 O
patients O
) O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
was O
+5.0 O
mg/dL O
for O
SEROQUEL O
and O
-0.05 O
mg/dL O
for O
placebo O
. O

The O
exposure-adjusted O
rate O
of O
any O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
level I-OSE_Labeled_AE
( O
> O
= O
126 O
mg/dL O
) O
for O
patients O
more O
than O
8 O
hours O
since O
a O
meal O
( O
however O
, O
some O
patients O
may O
not O
have O
been O
precluded O
from O
calorie O
intake O
from O
fluids O
during O
fasting O
period O
) O
was O
18.0 O
per O
100 O
patient O
years O
for O
SEROQUEL O
( O
10.7 O
% O
of O
patients O
; O
n=556 O
) O
and O
9.5 O
for O
placebo O
per O
100 O
patient O
years O
( O
4.6 O
% O
of O
patients O
; O
n=581 O
) O
. O

Children O
and O
Adolescents O
: O
In O
a O
placebo-controlled O
SEROQUEL O
monotherapy O
study O
of O
adolescent O
patients O
( O
13-17 O
years O
of O
age O
) O
with O
schizophrenia B-Not_AE_Candidate
( O
6 O
weeks O
duration O
) O
, O
the O
mean O
change B-NonOSE_AE
in I-NonOSE_AE
fasting I-NonOSE_AE
glucose I-NonOSE_AE
levels I-NonOSE_AE
for O
SEROQUEL O
( O
n=138 O
) O
compared O
to O
placebo O
( O
n=67 O
) O
was O
-0.75 O
mg/dL O
versus O
-1.70 O
mg/dL O
. O

In O
a O
placebo-controlled O
SEROQUEL O
monotherapy O
study O
of O
children O
and O
adolescent O
patients O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3 O
weeks O
duration O
) O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
level I-OSE_Labeled_AE
for O
SEROQUEL O
( O
n=170 O
) O
compared O
to O
placebo O
( O
n=81 O
) O
was O
3.62 O
mg/dL O
versus O
-1.17 O
mg/dL O
. O

No O
patient O
in O
either O
study O
with O
a O
baseline O
normal B-Not_AE_Candidate
fasting I-Not_AE_Candidate
glucose I-Not_AE_Candidate
level I-Not_AE_Candidate
( I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mg I-Not_AE_Candidate
/ I-Not_AE_Candidate
dL I-Not_AE_Candidate
) O
or O
a O
baseline O
borderline B-Not_AE_Candidate
fasting I-Not_AE_Candidate
glucose I-Not_AE_Candidate
level I-Not_AE_Candidate
( I-Not_AE_Candidate
> I-Not_AE_Candidate
= I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mg I-Not_AE_Candidate
/ I-Not_AE_Candidate
dL I-Not_AE_Candidate
and I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
2 I-Not_AE_Candidate
6 I-Not_AE_Candidate
mg I-Not_AE_Candidate
/ I-Not_AE_Candidate
dL I-Not_AE_Candidate
) O
had O
a O
treatment-emergent O
blood B-NonOSE_AE
glucose I-NonOSE_AE
level I-NonOSE_AE
of I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
6 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
. O

In O
a O
placebo-controlled O
SEROQUEL O
XR O
monotherapy O
study O
( O
8 O
weeks O
duration O
) O
of O
children O
and O
adolescent O
patients O
( O
10 O
- O
17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
for O
SEROQUEL O
XR O
( O
n O
= O
60 O
) O
compared O
to O
placebo O
( O
n O
= O
62 O
) O
was O
1.8 O
mg/dL O
versus O
1.6 O
mg/dL O
. O

In O
this O
study O
, O
there O
were O
no O
patients O
in O
the O
SEROQUEL O
XR O
or O
placebo-treated O
groups O
with O
a O
baseline O
normal O
fasting O
glucose O
level O
( O
< O
100 O
mg/dL O
) O
that O
had O
an O
increase B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
glucose I-NonOSE_AE
level I-NonOSE_AE
> I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
6 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
. O

There O
was O
one O
patient O
in O
the O
SEROQUEL O
XR O
group O
with O
a O
baseline O
borderline B-Not_AE_Candidate
fasting I-Not_AE_Candidate
glucose I-Not_AE_Candidate
level I-Not_AE_Candidate
( I-Not_AE_Candidate
> I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mg I-Not_AE_Candidate
/ I-Not_AE_Candidate
dL I-Not_AE_Candidate
and I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
2 I-Not_AE_Candidate
6 I-Not_AE_Candidate
mg I-Not_AE_Candidate
/ I-Not_AE_Candidate
dL I-Not_AE_Candidate
) O
who O
had O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
level O
of O
> O
126 O
mg/dL O
compared O
to O
zero O
patients O
in O
the O
placebo O
group O
. O

Dyslipidemia B-OSE_Labeled_AE
Adults O
: O
Table O
4 O
shows O
the O
percentage O
of O
adult O
patients O
with O
changes B-NonOSE_AE
in I-NonOSE_AE
total I-NonOSE_AE
cholesterol I-NonOSE_AE
, O
triglycerides O
, O
LDL-cholesterol O
and O
HDL-cholesterol O
from O
baseline O
by O
indication O
in O
clinical O
trials O
with O
SEROQUEL O
. O

Table O
4 O
: O
Percentage O
of O
Adult O
Patients O
with O
Shifts O
in O
Total O
Cholesterol O
, O
Triglycerides O
, O
LDL-Cholesterol O
and O
HDL-Cholesterol O
from O
Baseline O
to O
Clinically O
Significant O
Levels O
by O
Indication O
Laboratory O
Analyte O
Indication O
Treatment O
Arm O
N O
Patients O
n O
( O
% O
) O
Total B-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
6 I-Not_AE_Candidate
weeks O
duration O
SEROQUEL O
137 O
24 O
( O
18 O
% O
) O
Placebo O
92 O
6 O
( O
7 O
% O
) O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
8 I-Not_AE_Candidate
weeks O
duration O
SEROQUEL O
463 O
41 O
( O
9 O
% O
) O
Placebo O
250 O
15 O
( O
6 O
% O
) O
Triglycerides B-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
120 O
26 O
( O
22 O
% O
) O
Placebo O
70 O
11 O
( O
16 O
% O
) O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
SEROQUEL O
436 O
59 O
( O
14 O
% O
) O
Placebo O
232 O
20 O
( O
9 O
% O
) O
LDL B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
naParameters O
not O
measured O
in O
the O
SEROQUEL O
registration O
studies O
for O
schizophrenia B-Not_AE_Candidate
. O

Lipid O
parameters O
also O
were O
not O
measured O
in O
the O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
registration O
studies O
. O

na O
Placebo O
na O
na O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
SEROQUEL O
465 O
29 O
( O
6 O
% O
) O
Placebo O
256 O
12 O
( O
5 O
% O
) O
HDL B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
< I-OSE_Labeled_AE
= I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
na O
na O
Placebo O
na O
na O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
SEROQUEL O
393 O
56 O
( O
14 O
% O
) O
Placebo O
214 O
29 O
( O
14 O
% O
) O
Children O
and O
Adolescents O
: O
Table O
5 O
shows O
the O
percentage O
of O
children O
and O
adolescents O
with O
changes B-NonOSE_AE
in I-NonOSE_AE
total I-NonOSE_AE
cholesterol I-NonOSE_AE
, O
triglycerides O
, O
LDL-cholesterol O
and O
HDL-cholesterol O
from O
baseline O
in O
clinical O
trials O
with O
SEROQUEL O
. O

Table O
5 O
: O
Percentage O
of O
Children O
and O
Adolescents O
with O
Shifts O
in O
Total O
Cholesterol O
, O
Triglycerides O
, O
LDL-Cholesterol O
and O
HDL-Cholesterol O
from O
Baseline O
to O
Clinically O
Significant O
Levels O
Laboratory O
Analyte O
Indication O
Treatment O
Arm O
N O
Patients O
n O
( O
% O
) O
Total B-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
1 I-Not_AE_Candidate
3 I-Not_AE_Candidate
- I-Not_AE_Candidate
1 I-Not_AE_Candidate
7 I-Not_AE_Candidate
years O
, O
6 O
weeks O
duration O
SEROQUEL O
107 O
13 O
( O
12 O
% O
) O
Placebo O
56 O
1 O
( O
2 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
- I-Not_AE_Candidate
1 I-Not_AE_Candidate
7 I-Not_AE_Candidate
years O
, O
3 O
weeks O
duration O
SEROQUEL O
159 O
16 O
( O
10 O
% O
) O
Placebo O
66 O
2 O
( O
3 O
% O
) O
Triglycerides B-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
103 O
17 O
( O
17 O
% O
) O
Placebo O
51 O
4 O
( O
8 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
SEROQUEL O
149 O
32 O
( O
22 O
% O
) O
Placebo O
60 O
8 O
( O
13 O
% O
) O
LDL B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
112 O
4 O
( O
4 O
% O
) O
Placebo O
60 O
1 O
( O
2 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
SEROQUEL O
169 O
13 O
( O
8 O
% O
) O
Placebo O
74 O
4 O
( O
5 O
% O
) O
HDL B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
< I-OSE_Labeled_AE
= I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
104 O
16 O
( O
15 O
% O
) O
Placebo O
54 O
10 O
( O
19 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
SEROQUEL O
154 O
16 O
( O
10 O
% O
) O
Placebo O
61 O
4 O
( O
7 O
% O
) O
In O
a O
placebo-controlled O
SEROQUEL O
XR O
monotherapy O
study O
( O
8 O
weeks O
duration O
) O
of O
children O
and O
adolescent O
patients O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
the O
percentage O
of O
children O
and O
adolescents O
with O
shifts O
in O
total B-NonOSE_AE
cholesterol I-NonOSE_AE
( I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
2 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
, O
triglycerides B-NonOSE_AE
( I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
, O
LDL B-NonOSE_AE
- I-NonOSE_AE
cholesterol I-NonOSE_AE
( I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
3 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
and O
HDL B-NonOSE_AE
- I-NonOSE_AE
cholesterol I-NonOSE_AE
( I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
4 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
from B-NonOSE_AE
baseline I-NonOSE_AE
to I-NonOSE_AE
clinically I-NonOSE_AE
significant I-NonOSE_AE
levels I-NonOSE_AE
were O
: O
total O
cholesterol O
8 O
% O
( O
7/83 O
) O
for O
SEROQUEL O
XR O
vs O
. O
6 O
% O
( O
5/84 O
) O
for O
placebo O
; O
triglycerides O
28 O
% O
( O
22/80 O
) O
for O
SEROQUEL O
XR O
vs O
. O
9 O
% O
( O
7/82 O
) O
for O
placebo O
; O
LDL I-NonOSE_AE
- I-NonOSE_AE
cholesterol I-NonOSE_AE
2 O
% O
( O
2/86 O
) O
for O
SEROQUEL O
XR O
vs O
. O
4 O
% O
( O
3/85 O
) O
for O
placebo O
and O
HDL-cholesterol O
20 O
% O
( O
13/65 O
) O
for O
SEROQUEL O
XR O
vs O
. O
15 O
% O
( O
11/74 O
) O
for O
placebo O
. O

Weight O
Gain O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
have O
been O
observed O
in O
clinical O
trials O
. O

Patients O
receiving O
quetiapine O
should O
receive O
regular O
monitoring O
of O
weight O
. O

Adults O
: O
In O
clinical O
trials O
with O
SEROQUEL O
the O
following O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
have O
been O
reported O
. O

Table O
6 O
: O
Proportion O
of O
Patients O
with O
Weight O
Gain O
> O
=7 O
% O
of O
Body O
Weight O
( O
Adults O
) O
Vital O
Sign O
Indication O
Treatment O
Arm O
N O
Patients O
n O
( O
% O
) O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
> O
=7 O
% O
of O
Body O
Weight O
Schizophreniaup B-Not_AE_Candidate
to O
6 O
weeks O
duration O
SEROQUEL O
391 O
89 O
( O
23 O
% O
) O
Placebo O
206 O
11 O
( O
6 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
( O
monotherapy O
) O
up O
to O
12 O
weeks O
duration O
SEROQUEL O
209 O
44 O
( O
21 O
% O
) O
Placebo O
198 O
13 O
( O
7 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
( O
adjunct O
therapy O
) O
up O
to O
3 O
weeks O
duration O
SEROQUEL O
196 O
25 O
( O
13 O
% O
) O
Placebo O
203 O
8 O
( O
4 O
% O
) O
Bipolar B-Not_AE_Candidate
Depressionup I-Not_AE_Candidate
to O
8 O
weeks O
duration O
SEROQUEL O
554 O
47 O
( O
8 O
% O
) O
Placebo O
295 O
7 O
( O
2 O
% O
) O
Children O
and O
Adolescents O
: O
In O
two O
clinical O
trials O
with O
SEROQUEL O
, O
one O
in O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
and O
one O
in O
schizophrenia B-Not_AE_Candidate
, O
reported O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
are O
included O
in O
table O
7 O
. O

Table O
7 O
: O
Proportion O
of O
Patients O
with O
Weight O
Gain O
> O
=7 O
% O
of O
Body O
Weight O
( O
Children O
and O
Adolescents O
) O
Vital O
Sign O
Indication O
Treatment O
Arm O
N O
Patients O
n O
( O
% O
) O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
> O
=7 O
% O
of O
Body O
Weight O
Schizophrenia B-Not_AE_Candidate
6 O
weeks O
duration O
SEROQUEL O
111 O
23 O
( O
21 O
% O
) O
Placebo O
44 O
3 O
( O
7 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
3 O
weeks O
duration O
SEROQUEL O
157 O
18 O
( O
12 O
% O
) O
Placebo O
68 O
0 O
( O
0 O
% O
) O
The O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
in O
the O
schizophrenia B-Not_AE_Candidate
trial O
was O
2.0 O
kg O
in O
the O
SEROQUEL O
group O
and O
-0.4 O
kg O
in O
the O
placebo O
group O
and O
in O
the O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trial O
, O
it O
was O
1.7 O
kg O
in O
the O
SEROQUEL O
group O
and O
0.4 O
kg O
in O
the O
placebo O
group O
. O

In O
an O
open-label O
study O
that O
enrolled O
patients O
from O
the O
above O
two O
pediatric O
trials O
, O
63 O
% O
of O
patients O
( O
241/380 O
) O
completed O
26 O
weeks O
of O
therapy O
with O
SEROQUEL O
. O

After O
26 O
weeks O
of O
treatment O
, O
the O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
was O
4.4 O
kg O
. O

Forty-five O
percent O
of O
the O
patients O
gained B-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
of I-OSE_Labeled_AE
their I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
not O
adjusted O
for O
normal O
growth O
. O

In O
order O
to O
adjust O
for O
normal O
growth O
over O
26 O
weeks O
an O
increase O
of O
at O
least O
0.5 O
standard O
deviation O
from O
baseline O
in O
BMI O
was O
used O
as O
a O
measure O
of O
a O
clinically O
significant O
change O
; O
18.3 O
% O
of O
patients O
on O
SEROQUEL O
met O
this O
criterion O
after O
26 O
weeks O
of O
treatment O
. O

In O
a O
clinical O
trial O
for O
SEROQUEL O
XR O
in O
children O
and O
adolescents O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
the O
percentage O
of O
patients O
with O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
> O
=7 O
% O
of O
body O
weight O
at O
any O
time O
was O
15 O
% O
( O
14/92 O
) O
for O
SEROQUEL O
XR O
vs O
. O
10 O
% O
( O
10/100 O
) O
for O
placebo O
. O

The O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
was I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
in O
the O
SEROQUEL O
XR O
group O
vs O
. O
0.6 O
kg O
in O
the O
placebo O
group O
. O

When O
treating O
pediatric O
patients O
with O
SEROQUEL O
for O
any O
indication O
, O
weight B-NonOSE_AE
gain I-NonOSE_AE
should O
be O
assessed O
against O
that O
expected O
for O
normal O
growth O
. O

5.6 O
Tardive B-OSE_Labeled_AE
Dyskinesia I-OSE_Labeled_AE
A O
syndrome O
of O
potentially O
irreversible O
, O
involuntary O
, O
dyskinetic B-OSE_Labeled_AE
movements I-OSE_Labeled_AE
may O
develop O
in O
patients O
treated O
with O
antipsychotic O
drugs O
, O
including O
quetiapine O
. O

Although O
the O
prevalence O
of O
the O
syndrome O
appears O
to O
be O
highest O
among O
the O
elderly O
, O
especially O
elderly O
women O
, O
it O
is O
impossible O
to O
rely O
upon O
prevalence O
estimates O
to O
predict O
, O
at O
the O
inception O
of O
antipsychotic O
treatment O
, O
which O
patients O
are O
likely O
to O
develop O
the O
syndrome O
. O

Whether O
antipsychotic O
drug O
products O
differ O
in O
their O
potential O
to O
cause O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
is O
unknown O
. O

The O
risk O
of O
developing O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
and O
the O
likelihood O
that O
it O
will O
become O
irreversible O
are O
believed O
to O
increase O
as O
the O
duration O
of O
treatment O
and O
the O
total O
cumulative O
dose O
of O
antipsychotic O
drugs O
administered O
to O
the O
patient O
increase O
. O

However O
, O
the O
syndrome O
can O
develop O
, O
although O
much O
less O
commonly O
, O
after O
relatively O
brief O
treatment O
periods O
at O
low O
doses O
or O
may O
even O
arise O
after O
discontinuation O
of O
treatment O
. O

There O
is O
no O
known O
treatment O
for O
established O
cases O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
, O
although O
the O
syndrome O
may O
remit O
, O
partially O
or O
completely O
, O
if O
antipsychotic O
treatment O
is O
withdrawn O
. O

Antipsychotic O
treatment O
, O
itself O
, O
however O
, O
may O
suppress O
( O
or O
partially O
suppress O
) O
the O
signs O
and O
symptoms O
of O
the O
syndrome O
and O
thereby O
may O
possibly O
mask O
the O
underlying O
process O
. O

The O
effect O
that O
symptomatic O
suppression O
has O
upon O
the O
long-term O
course O
of O
the O
syndrome O
is O
unknown O
. O

Given O
these O
considerations O
, O
SEROQUEL O
should O
be O
prescribed O
in O
a O
manner O
that O
is O
most O
likely O
to O
minimize O
the O
occurrence O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
. O

Chronic O
antipsychotic O
treatment O
should O
generally O
be O
reserved O
for O
patients O
who O
appear O
to O
suffer O
from O
a O
chronic O
illness O
that O
( O
1 O
) O
is O
known O
to O
respond O
to O
antipsychotic O
drugs O
, O
and O
( O
2 O
) O
for O
whom O
alternative O
, O
equally O
effective O
, O
but O
potentially O
less O
harmful O
treatments O
are O
not O
available O
or O
appropriate O
. O

In O
patients O
who O
do O
require O
chronic O
treatment O
, O
the O
smallest O
dose O
and O
the O
shortest O
duration O
of O
treatment O
producing O
a O
satisfactory O
clinical O
response O
should O
be O
sought O
. O

The O
need O
for O
continued O
treatment O
should O
be O
reassessed O
periodically O
. O

If O
signs O
and O
symptoms O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
appear O
in O
a O
patient O
on O
SEROQUEL O
, O
drug O
discontinuation O
should O
be O
considered O
. O

However O
, O
some O
patients O
may O
require O
treatment O
with O
SEROQUEL O
despite O
the O
presence O
of O
the O
syndrome O
. O

5.7 O
Hypotension O
Quetiapine O
may O
induce O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
associated O
with O
dizziness B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
and O
, O
in O
some O
patients O
, O
syncope B-NonOSE_AE
, O
especially O
during O
the O
initial O
dose-titration O
period O
, O
probably O
reflecting O
its O
alpha1-adrenergic O
antagonist O
properties O
. O

Syncope B-OSE_Labeled_AE
was O
reported O
in O
1 O
% O
( O
28/3265 O
) O
of O
the O
patients O
treated O
with O
SEROQUEL O
, O
compared O
with O
0.2 O
% O
( O
2/954 O
) O
on O
placebo O
and O
about O
0.4 O
% O
( O
2/527 O
) O
on O
active O
control O
drugs O
. O

Orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
and O
syncope B-NonOSE_AE
may O
lead O
to O
falls B-NonOSE_AE
. O

SEROQUEL O
should O
be O
used O
with O
particular O
caution O
in O
patients O
with O
known O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
history O
of O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
or O
ischemic B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
or O
conduction B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
) O
, O
cerebrovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
conditions O
which O
would O
predispose O
patients O
to O
hypotension B-NonOSE_AE
( O
dehydration B-Not_AE_Candidate
, O
hypovolemia B-Not_AE_Candidate
and O
treatment O
with O
antihypertensive B-NonOSE_AE
medications I-NonOSE_AE
) O
. O

The O
risk O
of O
orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
and O
syncope B-NonOSE_AE
may O
be O
minimized O
by O
limiting O
the O
initial O
dose O
to O
25 O
mg O
twice O
daily O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

If O
hypotension B-NonOSE_AE
occurs O
during O
titration O
to O
the O
target O
dose O
, O
a O
return O
to O
the O
previous O
dose O
in O
the O
titration O
schedule O
is O
appropriate O
. O

5.8 O
Falls O
Atypical O
antipsychotic O
drugs O
, O
including O
SEROQUEL O
, O
may O
cause O
somnolence B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
motor B-OSE_Labeled_AE
and O
sensory O
instability I-OSE_Labeled_AE
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
and O
, O
consequently O
, O
fractures B-NonOSE_AE
or O
other O
injuries O
. O

For O
patients O
with O
diseases O
, O
conditions O
, O
or O
medications O
that O
could O
exacerbate O
these O
effects O
, O
complete O
fall B-NonOSE_AE
risk O
assessments O
when O
initiating O
antipsychotic O
treatment O
and O
recurrently O
for O
patients O
on O
long-term O
antipsychotic O
therapy O
. O

5.9 O
Increases O
in O
Blood O
Pressure O
( O
Children O
and O
Adolescents O
) O
In O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
schizophrenia B-Not_AE_Candidate
( O
6-week O
duration O
) O
or O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3-week O
duration O
) O
, O
the O
incidence O
of O
increases B-OSE_Labeled_AE
at O
any O
time O
in I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
> O
=20 O
mmHg O
) O
was O
15.2 O
% O
( O
51/335 O
) O
for O
SEROQUEL O
and O
5.5 O
% O
( O
9/163 O
) O
for O
placebo O
; O
the O
incidence O
of O
increases B-OSE_Labeled_AE
at O
any O
time O
in I-OSE_Labeled_AE
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
> O
=10 O
mmHg O
) O
was O
40.6 O
% O
( O
136/335 O
) O
for O
SEROQUEL O
and O
24.5 O
% O
( O
40/163 O
) O
for O
placebo O
. O

In O
the O
26-week O
open-label O
clinical O
trial O
, O
one O
child O
with O
a O
reported O
history O
of O
hypertension B-Not_AE_Candidate
experienced O
a O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
. O

Blood O
pressure O
in O
children O
and O
adolescents O
should O
be O
measured O
at O
the O
beginning O
of O
, O
and O
periodically O
during O
treatment O
. O

In O
a O
placebo-controlled O
SEROQUEL O
XR O
clinical O
trial O
( O
8 O
weeks O
duration O
) O
in O
children O
and O
adolescents O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
the O
incidence O
of O
increases B-OSE_Labeled_AE
at O
any O
time O
in I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
> O
=20 O
mmHg O
) O
was O
6.5 O
% O
( O
6/92 O
) O
for O
SEROQUEL O
XR O
and O
6.0 O
% O
( O
6/100 O
) O
for O
placebo O
; O
the O
incidence O
of O
increases B-OSE_Labeled_AE
at O
any O
time O
in I-OSE_Labeled_AE
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
> O
=10 O
mmHg O
) O
was O
46.7 O
% O
( O
43/92 O
) O
for O
SEROQUEL O
XR O
and O
36.0 O
% O
( O
36/100 O
) O
for O
placebo O
. O

5.10 O
Leukopenia O
, O
Neutropenia O
and O
Agranulocytosis O
In O
clinical O
trial O
and O
postmarketing O
experience O
, O
events O
of O
leukopenia B-OSE_Labeled_AE
/ O
neutropenia B-OSE_Labeled_AE
have O
been O
reported O
temporally O
related O
to O
atypical O
antipsychotic O
agents O
, O
including O
SEROQUEL O
. O

Agranulocytosis B-OSE_Labeled_AE
( O
including O
fatal B-NonOSE_AE
cases O
) O
has O
also O
been O
reported O
. O

Possible O
risk O
factors O
for O
leukopenia B-NonOSE_AE
/ O
neutropenia B-NonOSE_AE
include O
pre-existing O
low B-Not_AE_Candidate
white I-Not_AE_Candidate
cell I-Not_AE_Candidate
count I-Not_AE_Candidate
( I-Not_AE_Candidate
WBC I-Not_AE_Candidate
) O
and O
history O
of O
drug B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia/ O
neutropenia I-Not_AE_Candidate
. O

Patients O
with O
a O
pre-existing O
low B-Not_AE_Candidate
WBC I-Not_AE_Candidate
or O
a O
history O
of O
drug B-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia I-Not_AE_Candidate
/neutropenia O
should O
have O
their O
complete O
blood O
count O
( O
CBC O
) O
monitored O
frequently O
during O
the O
first O
few O
months O
of O
therapy O
and O
should O
discontinue O
SEROQUEL O
at O
the O
first O
sign O
of O
a O
decline B-NonOSE_AE
in I-NonOSE_AE
WBC I-NonOSE_AE
in O
absence O
of O
other O
causative O
factors O
. O

Patients O
with O
neutropenia B-NonOSE_AE
should O
be O
carefully O
monitored O
for O
fever B-NonOSE_AE
or O
other O
symptoms O
or O
signs O
of O
infection B-NonOSE_AE
and O
treated O
promptly O
if O
such O
symptoms O
or O
signs O
occur O
. O

Patients O
with O
severe O
neutropenia B-NonOSE_AE
( O
absolute B-NonOSE_AE
neutrophil I-NonOSE_AE
count I-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
) O
should O
discontinue O
SEROQUEL O
and O
have O
their O
WBC O
followed O
until O
recovery O
. O

5.11 O
Cataracts O
The O
development O
of O
cataracts B-NonOSE_AE
was O
observed O
in O
association O
with O
quetiapine O
treatment O
in O
chronic O
dog O
studies O
[ O
see O
Nonclinical O
Toxicology O
( O
13.2 O
) O
] O
. O

Lens B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
have O
also O
been O
observed O
in O
adults O
, O
children O
and O
adolescents O
during O
long-term O
SEROQUEL O
treatment O
, O
but O
a O
causal O
relationship O
to O
SEROQUEL O
use O
has O
not O
been O
established O
. O

Nevertheless O
, O
the O
possibility O
of O
lenticular B-NonOSE_AE
changes I-NonOSE_AE
can O
not O
be O
excluded O
at O
this O
time O
. O

Therefore O
, O
examination O
of O
the O
lens O
by O
methods O
adequate O
to O
detect O
cataract B-NonOSE_AE
formation I-NonOSE_AE
, O
such O
as O
slit O
lamp O
exam O
or O
other O
appropriately O
sensitive O
methods O
, O
is O
recommended O
at O
initiation O
of O
treatment O
or O
shortly O
thereafter O
, O
and O
at O
6-month O
intervals O
during O
chronic O
treatment O
. O

5.12 O
QT O
Prolongation O
In O
clinical O
trials O
, O
quetiapine O
was O
not O
associated O
with O
a O
persistent O
increase B-NonOSE_AE
in I-NonOSE_AE
QT I-NonOSE_AE
intervals I-NonOSE_AE
. O

However O
, O
the O
QT O
effect O
was O
not O
systematically O
evaluated O
in O
a O
thorough O
QT O
study O
. O

In O
post O
marketing O
experience O
, O
there O
were O
cases O
reported O
of O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
in O
patients O
who O
overdosed O
on O
quetiapine O
[ O
see O
Overdosage O
( O
10.1 O
) O
] O
, O
in O
patients O
with O
concomitant O
illness O
, O
and O
in O
patients O
taking O
medicines O
known O
to O
cause O
electrolyte B-Not_AE_Candidate
imbalance I-Not_AE_Candidate
or O
increase B-Not_AE_Candidate
QT I-Not_AE_Candidate
interval I-Not_AE_Candidate
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

The O
use O
of O
quetiapine O
should O
be O
avoided O
in O
combination O
with O
other O
drugs O
that O
are O
known O
to O
prolong B-NonOSE_AE
QTc I-NonOSE_AE
including O
Class O
1A O
antiarrythmics O
( O
e.g. O
, O
quinidine O
, O
procainamide O
) O
or O
Class O
III O
antiarrythmics O
( O
e.g. O
, O
amiodarone O
, O
sotalol O
) O
, O
antipsychotic O
medications O
( O
e.g. O
, O
ziprasidone O
, O
chlorpromazine O
, O
thioridazine O
) O
, O
antibiotics O
( O
e.g. O
, O
gatifloxacin O
, O
moxifloxacin O
) O
, O
or O
any O
other O
class O
of O
medications O
known O
to O
prolong B-NonOSE_AE
the I-NonOSE_AE
QTc I-NonOSE_AE
interval I-NonOSE_AE
( O
e.g. O
, O
pentamidine O
, O
levomethadyl O
acetate O
, O
methadone O
) O
. O

Quetiapine O
should O
also O
be O
avoided O
in O
circumstances O
that O
may O
increase O
the O
risk O
of O
occurrence O
of O
torsade B-NonOSE_AE
de I-NonOSE_AE
pointes I-NonOSE_AE
and/or O
sudden B-NonOSE_AE
death I-NonOSE_AE
including O
( O
1 O
) O
a O
history O
of O
cardiac B-Not_AE_Candidate
arrhythmias I-Not_AE_Candidate
such O
as O
bradycardia B-Not_AE_Candidate
; O
( O
2 O
) O
hypokalemia B-Not_AE_Candidate
or O
hypomagnesemia B-Not_AE_Candidate
; O
( O
3 O
) O
concomitant O
use O
of O
other O
drugs O
that O
prolong B-NonOSE_AE
the I-NonOSE_AE
QTc I-NonOSE_AE
interval I-NonOSE_AE
; O
and O
( O
4 O
) O
presence O
of O
congenital B-Not_AE_Candidate
prolongation I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
QT I-Not_AE_Candidate
interval I-Not_AE_Candidate
. O

Caution O
should O
also O
be O
exercised O
when O
quetiapine O
is O
prescribed O
in O
patients O
with O
increased O
risk O
of O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
( O
e.g. O
, O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
family O
history O
of O
QT B-Not_AE_Candidate
prolongation I-Not_AE_Candidate
, O
the O
elderly O
, O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
and O
heart B-Not_AE_Candidate
hypertrophy I-Not_AE_Candidate
) O
. O

5.13 O
Seizures O
During O
clinical O
trials O
, O
seizures B-OSE_Labeled_AE
occurred O
in O
0.5 O
% O
( O
20/3490 O
) O
of O
patients O
treated O
with O
SEROQUEL O
compared O
to O
0.2 O
% O
( O
2/954 O
) O
on O
placebo O
and O
0.7 O
% O
( O
4/527 O
) O
on O
active O
control O
drugs O
. O

As O
with O
other O
antipsychotics O
, O
SEROQUEL O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
or O
with O
conditions O
that O
potentially O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
, O
e.g. O
, O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
dementia I-Not_AE_Candidate
. O

Conditions O
that O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
may O
be O
more O
prevalent O
in O
a O
population O
of O
65 O
years O
or O
older O
. O

5.14 O
Hypothyroidism B-OSE_Labeled_AE
Adults O
: O
Clinical O
trials O
with O
quetiapine O
demonstrated O
dose-related O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

The O
reduction B-OSE_Labeled_AE
in O
total O
and O
free I-OSE_Labeled_AE
thyroxine I-OSE_Labeled_AE
( I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
) O
of O
approximately O
20 O
% O
at O
the O
higher O
end O
of O
the O
therapeutic O
dose O
range O
was O
maximal O
in O
the O
first O
six O
weeks O
of O
treatment O
and O
maintained O
without O
adaptation O
or O
progression O
during O
more O
chronic O
therapy O
. O

In O
nearly O
all O
cases O
, O
cessation O
of O
quetiapine O
treatment O
was O
associated O
with O
a O
reversal O
of O
the O
effects O
on O
total O
and O
free O
T4 O
, O
irrespective O
of O
the O
duration O
of O
treatment O
. O

The O
mechanism O
by O
which O
quetiapine O
effects O
the O
thyroid O
axis O
is O
unclear O
. O

If O
there O
is O
an O
effect O
on O
the O
hypothalamic-pituitary O
axis O
, O
measurement O
of O
TSH O
alone O
may O
not O
accurately O
reflect O
a O
patient O
's O
thyroid O
status O
. O

Therefore O
, O
both O
TSH O
and O
free O
T4 O
, O
in O
addition O
to O
clinical O
assessment O
, O
should O
be O
measured O
at O
baseline O
and O
at O
follow-up O
. O

In O
the O
mania B-Not_AE_Candidate
adjunct O
studies O
, O
where O
SEROQUEL O
was O
added O
to O
lithium O
or O
divalproex O
, O
12 O
% O
( O
24/196 O
) O
of O
SEROQUEL O
treated O
patients O
compared O
to O
7 O
% O
( O
15/203 O
) O
of O
placebo-treated O
patients O
had O
elevated B-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

Of O
the O
SEROQUEL O
treated O
patients O
with O
elevated B-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
3 O
had O
simultaneous O
low B-OSE_Labeled_AE
free I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
free O
T4 O
< O
0.8 O
LLN O
) O
. O

About O
0.7 O
% O
( O
26/3489 O
) O
of O
SEROQUEL O
patients O
did O
experience O
TSH B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
in O
monotherapy O
studies O
. O

Some O
patients O
with O
TSH B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
needed O
replacement O
thyroid O
treatment O
. O

In O
all O
quetiapine O
trials O
, O
the O
incidence O
of O
significant O
shifts B-NonOSE_AE
in I-NonOSE_AE
thyroid I-NonOSE_AE
hormones I-NonOSE_AE
and O
TSH O
were O
[ O
note O
: O
Based O
on O
shifts O
from O
normal O
baseline O
to O
potentially O
clinically O
important O
value O
at O
any O
time O
post-baseline O
. O

Shifts B-NonOSE_AE
in I-NonOSE_AE
total I-NonOSE_AE
T I-NonOSE_AE
4 I-NonOSE_AE
, O
free O
T4 O
, O
total O
T3and O
free O
T3are O
defined O
as O
M0.8 O
x O
LLN O
( O
pmol/L O
) O
and O
shift B-NonOSE_AE
in I-NonOSE_AE
TSH I-NonOSE_AE
is O
> O
5 O
mlU/L O
at O
any O
time O
. O
] O

: O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
free I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
( O
free O
T4 O
< O
0.8 O
LLN O
) O
, O
2.0 O
% O
( O
357/17513 O
) O
; O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
, O
4.0 O
% O
( O
75/1861 O
) O
; O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
free I-OSE_Labeled_AE
T I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
, O
0.4 O
% O
( O
53/13766 O
) O
; O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
T I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
, O
2.0 O
% O
( O
26/1312 O
) O
, O
and O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
, O
4.9 O
% O
( O
956/19412 O
) O
. O

In O
eight O
patients O
, O
where O
TBG O
was O
measured O
, O
levels O
of O
TBG O
were O
unchanged O
. O

Table O
8 O
shows O
the O
incidence O
of O
these O
shifts O
in O
short-term O
placebo-controlled O
clinical O
trials O
. O

Table O
8 O
: O
Incidence O
of O
Shifts B-OSE_Labeled_AE
in O
Thyroid O
Hormone O
Levels O
and O
TSH O
in O
Short-Term O
Placebo-Controlled O
Clinical O
TrialsBased O
on O
shifts O
from O
normal O
baseline O
to O
potentially O
clinically O
important O
value O
at O
any O
time O
post-baseline O
. O

Shifts O
in O
total I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
, O
free O
T4 O
, O
total O
T3 O
and O
free O
T3 O
are O
defined O
as O
< O
0.8 O
x O
LLN O
( O
pmol/L O
) O
and O
shift B-NonOSE_AE
in I-NonOSE_AE
TSH I-NonOSE_AE
is O
> O
5 O
mlU/L O
at O
any O
time. O
, O
Includes O
SEROQUEL O
and O
SEROQUEL O
XR O
data O
. O

Total O
T4 O
Free O
T4 O
Total O
T3 O
Free O
T3 O
TSH O
Quetiapine O
Placebo O
Quetiapine O
Placebo O
Quetiapine O
Placebo O
Quetiapine O
Placebo O
Quetiapine O
Placebo O
3.4 O
% O
( O
37/1097 O
) O
0.6 O
% O
( O
4/651 O
) O
0.7 O
% O
( O
52/7218 O
) O
0.1 O
% O
( O
4/3668 O
) O
0.5 O
% O
( O
2/369 O
) O
0.0 O
% O
( O
0/113 O
) O
0.2 O
% O
( O
11/5673 O
) O
0.0 O
% O
( O
1/2679 O
) O
3.2 O
% O
( O
240/7587 O
) O
2.7 O
% O
( O
105/3912 O
) O
In O
short-term O
placebo-controlled O
monotherapy O
trials O
, O
the O
incidence O
of O
reciprocal O
, O
shifts O
in O
T3and O
TSH O
was O
0.0 O
% O
for O
both O
quetiapine O
( O
1/4800 O
) O
and O
placebo O
( O
0/2190 O
) O
and O
for O
T4and O
TSH O
the O
shifts O
were O
0.1 O
% O
( O
7/6154 O
) O
for O
quetiapine O
versus O
0.0 O
% O
( O
1/3007 O
) O
for O
placebo O
. O

Children O
and O
Adolescents O
: O
In O
acute O
placebo-controlled O
trials O
in O
children O
and O
adolescent O
patients O
with O
schizophrenia B-Not_AE_Candidate
( O
6-week O
duration O
) O
or O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3-week O
duration O
) O
, O
the O
incidence O
of O
shifts O
for O
thyroid O
function O
values O
at O
any O
time O
for O
SEROQUEL O
treated O
patients O
and O
placebo-treated O
patients O
for O
elevated B-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
was O
2.9 O
% O
( O
8/280 O
) O
vs O
. O
0.7 O
% O
( O
1/138 O
) O
, O
respectively O
and O
for O
decreased B-OSE_Labeled_AE
total I-OSE_Labeled_AE
thyroxine I-OSE_Labeled_AE
was O
2.8 O
% O
( O
8/289 O
) O
vs O
. O
0 O
% O
( O
0/145 O
, O
respectively O
) O
. O

Of O
the O
SEROQUEL O
treated O
patients O
with O
elevated B-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
levels O
, O
1 O
had O
simultaneous O
low B-OSE_Labeled_AE
free I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
level O
at O
end O
of O
treatment O
. O

5.15 O
Hyperprolactinemia B-OSE_Labeled_AE
Adults O
: O
During O
clinical O
trials O
with O
quetiapine O
, O
the O
incidence O
of O
shifts B-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
clinically I-OSE_Labeled_AE
significant I-OSE_Labeled_AE
value I-OSE_Labeled_AE
occurred O
in O
3.6 O
% O
( O
158/4416 O
) O
of O
patients O
treated O
with O
quetiapine O
compared O
to O
2.6 O
% O
( O
51/1968 O
) O
on O
placebo O
. O

Children O
and O
Adolescents O
: O
In O
acute O
placebo-controlled O
trials O
in O
children O
and O
adolescent O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3-week O
duration O
) O
or O
schizophrenia B-Not_AE_Candidate
( O
6-week O
duration O
) O
, O
the O
incidence O
of O
shifts B-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
value I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
ug I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
males O
; O
> O
26 O
ug/L O
females O
at O
any O
time O
) O
was O
13.4 O
% O
( O
18/134 O
) O
for O
SEROQUEL O
compared O
to O
4 O
% O
( O
3/75 O
) O
for O
placebo O
in O
males O
and O
8.7 O
% O
( O
9/104 O
) O
for O
SEROQUEL O
compared O
to O
0 O
% O
( O
0/39 O
) O
for O
placebo O
in O
females O
. O

Like O
other O
drugs O
that O
antagonize O
dopamine O
D2receptors O
, O
SEROQUEL O
elevates B-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
in O
some O
patients O
and O
the O
elevation O
may O
persist O
during O
chronic O
administration O
. O

Hyperprolactinemia B-NonOSE_AE
, O
regardless O
of O
etiology O
, O
may O
suppress B-NonOSE_AE
hypothalamic I-NonOSE_AE
GnRH I-NonOSE_AE
, O
resulting O
in O
reduced B-NonOSE_AE
pituitary I-NonOSE_AE
gonadotrophin I-NonOSE_AE
secretion I-NonOSE_AE
. O

This O
, O
in O
turn O
, O
may O
inhibit B-NonOSE_AE
reproductive I-NonOSE_AE
function I-NonOSE_AE
by O
impairing B-NonOSE_AE
gonadal I-NonOSE_AE
steroidogenesis I-NonOSE_AE
in O
both O
female O
and O
male O
patients O
. O

Galactorrhea B-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
receiving O
prolactin B-NonOSE_AE
- I-NonOSE_AE
elevating I-NonOSE_AE
compounds O
. O

Long-standing O
hyperprolactinemia B-NonOSE_AE
when O
associated O
with O
hypogonadism B-NonOSE_AE
may O
lead O
to O
decreased B-NonOSE_AE
bone I-NonOSE_AE
density I-NonOSE_AE
in O
both O
female O
and O
male O
subjects O
. O

Tissue O
culture O
experiments O
indicate O
that O
approximately O
one-third O
of O
human O
breast B-NonOSE_AE
cancers I-NonOSE_AE
are O
prolactin O
dependent O
in O
vitro O
, O
a O
factor O
of O
potential O
importance O
if O
the O
prescription O
of O
these O
drugs O
is O
considered O
in O
a O
patient O
with O
previously O
detected O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

As O
is O
common O
with O
compounds O
which O
increase B-NonOSE_AE
prolactin I-NonOSE_AE
release O
, O
mammary B-NonOSE_AE
gland I-NonOSE_AE
, O
and O
pancreatic O
islet O
cell O
neoplasia I-NonOSE_AE
( O
mammary B-NonOSE_AE
adenocarcinomas I-NonOSE_AE
, O
pituitary B-NonOSE_AE
and O
pancreatic O
adenomas I-NonOSE_AE
) O
was O
observed O
in O
carcinogenicity B-NonOSE_AE
studies O
conducted O
in O
mice O
and O
rats O
. O

Neither O
clinical O
studies O
nor O
epidemiologic O
studies O
conducted O
to O
date O
have O
shown O
an O
association O
between O
chronic O
administration O
of O
this O
class O
of O
drugs O
and O
tumorigenesis B-NonOSE_AE
in O
humans O
, O
but O
the O
available O
evidence O
is O
too O
limited O
to O
be O
conclusive O
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

5.16 O
Potential O
for O
Cognitive B-OSE_Labeled_AE
and O
Motor O
Impairment I-OSE_Labeled_AE
Somnolence B-OSE_Labeled_AE
was O
a O
commonly O
reported O
adverse O
event O
reported O
in O
patients O
treated O
with O
SEROQUEL O
especially O
during O
the O
3-5 O
day O
period O
of O
initial O
dose-titration O
. O

In O
schizophrenia B-Not_AE_Candidate
trials O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
in O
18 O
% O
( O
89/510 O
) O
of O
patients O
on O
SEROQUEL O
compared O
to O
11 O
% O
( O
22/206 O
) O
of O
placebo O
patients O
. O

In O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trials O
using O
SEROQUEL O
as O
monotherapy O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
in O
16 O
% O
( O
34/209 O
) O
of O
patients O
on O
SEROQUEL O
compared O
to O
4 O
% O
of O
placebo O
patients O
. O

In O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trials O
using O
SEROQUEL O
as O
adjunct O
therapy O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
in O
34 O
% O
( O
66/196 O
) O
of O
patients O
on O
SEROQUEL O
compared O
to O
9 O
% O
( O
19/203 O
) O
of O
placebo O
patients O
. O

In O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
trials O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
in O
57 O
% O
( O
398/698 O
) O
of O
patients O
on O
SEROQUEL O
compared O
to O
15 O
% O
( O
51/347 O
) O
of O
placebo O
patients O
. O

Since O
SEROQUEL O
has O
the O
potential O
to O
impair B-OSE_Labeled_AE
judgment O
, O
thinking O
, O
or O
motor I-OSE_Labeled_AE
skills I-OSE_Labeled_AE
, O
patients O
should O
be O
cautioned O
about O
performing O
activities O
requiring O
mental O
alertness O
, O
such O
as O
operating O
a O
motor O
vehicle O
( O
including O
automobiles O
) O
or O
operating O
hazardous O
machinery O
until O
they O
are O
reasonably O
certain O
that O
SEROQUEL O
therapy O
does O
not O
affect O
them O
adversely O
. O

Somnolence B-OSE_Labeled_AE
may O
lead O
to O
falls B-NonOSE_AE
. O

5.17 O
Body O
Temperature O
Regulation O
Although O
not O
reported O
with O
SEROQUEL O
, O
disruption B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
body I-NonOSE_AE
' I-NonOSE_AE
s I-NonOSE_AE
ability I-NonOSE_AE
to I-NonOSE_AE
reduce I-NonOSE_AE
core I-NonOSE_AE
body I-NonOSE_AE
temperature I-NonOSE_AE
has O
been O
attributed O
to O
antipsychotic O
agents O
. O

Appropriate O
care O
is O
advised O
when O
prescribing O
SEROQUEL O
for O
patients O
who O
will O
be O
experiencing O
conditions O
which O
may O
contribute O
to O
an O
elevation B-NonOSE_AE
in I-NonOSE_AE
core I-NonOSE_AE
body I-NonOSE_AE
temperature I-NonOSE_AE
, O
e.g. O
, O
exercising O
strenuously O
, O
exposure O
to O
extreme O
heat O
, O
receiving O
concomitant O
medication O
with O
anticholinergic O
activity O
, O
or O
being O
subject O
to O
dehydration B-NonOSE_AE
. O

5.18 O
Dysphagia B-OSE_Labeled_AE
Esophageal B-OSE_Labeled_AE
dysmotility I-OSE_Labeled_AE
and O
aspiration B-OSE_Labeled_AE
have O
been O
associated O
with O
antipsychotic O
drug O
use O
. O

Aspiration B-NonOSE_AE
pneumonia I-NonOSE_AE
is O
a O
common O
cause O
of O
morbidity O
and O
mortality B-NonOSE_AE
in O
elderly O
patients O
, O
in O
particular O
those O
with O
advanced O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
dementia I-Not_AE_Candidate
. O

SEROQUEL O
and O
other O
antipsychotic O
drugs O
should O
be O
used O
cautiously O
in O
patients O
at O
risk O
for O
aspiration B-Not_AE_Candidate
pneumonia I-Not_AE_Candidate
. O

5.19 O
Discontinuation O
Syndrome O
Acute B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
such O
as O
insomnia B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
and O
vomiting B-NonOSE_AE
have O
been O
described O
after O
abrupt O
cessation O
of O
atypical O
antipsychotic O
drugs O
, O
including O
SEROQUEL O
. O

In O
short-term O
placebo-controlled O
, O
monotherapy O
clinical O
trials O
with O
SEROQUEL O
XR O
that O
included O
a O
discontinuation O
phase O
which O
evaluated O
discontinuation B-NonOSE_AE
symptoms I-NonOSE_AE
, O
the O
aggregated O
incidence O
of O
patients O
experiencing O
one O
or O
more O
discontinuation B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
after O
abrupt O
cessation O
was O
12.1 O
% O
( O
241/1993 O
) O
for O
SEROQUEL O
XR O
and O
6.7 O
% O
( O
71/1065 O
) O
for O
placebo O
. O

The O
incidence O
of O
the O
individual O
adverse O
events O
( O
i.e. O
, O
insomnia B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
dizziness B-NonOSE_AE
and O
irritability B-NonOSE_AE
) O
did O
not O
exceed O
5.3 O
% O
in O
any O
treatment O
group O
and O
usually O
resolved O
after O
1 O
week O
post-discontinuation O
. O

Gradual O
withdrawal O
is O
advised O
. O

